Background: Febrile neutropenia (F&N) is common among pediatric oncology patients. However, there is a lack of clarity regarding parameters whereby such patients have demonstrated adequate bone marrow recovery for hospital discharge and empiric antibiotic discontinuation.
INTRODUCTION
Febrile neutropenia (F&N) is a common occurrence in pediatric oncology patients due to myelosuppressive chemotherapy. There is consensus that these episodes require inpatient hospitalization Abbreviations: AMC, absolute monocyte count; ANC, absolute neutrophil count; APC, absolute phagocyte count; BSI, blood stream infection; CVC, central venous catheter; F&N, febrile neutropenia; G-CSF, granulocyte colony stimulating factor; IV, intravenous and broad-spectrum parenteral antibiotics while evaluating for invasive bacterial disease. [1] [2] [3] However, less clarity exists regarding clinical parameters whereby such patients can be determined to have adequate count recovery for safe discharge home without further antibiotic treatment. Discharge criteria in many pediatric oncology programs and at this institution include afebrile status for ≥24 hr with negative blood cultures for ≥48 hr, and evidence of bone marrow recovery at the time of discharge. Absolute neutrophil count (ANC) is most commonly used as a surrogate marker for adequate bone marrow recovery. 4 Pediatric-specific guidelines propose a post-nadir ANC greater than 100/ l as a reasonable threshold value for evidence of bone marrow recovery and safety of discharge home without antibiotics. 3 However, no studies examining specific threshold criteria for evidence of bone marrow recovery and patient outcomes based on commonly used threshold ANC values have been reported to support these guidelines. [5] [6] [7] [8] Furthermore, the ANC threshold used remains variable across providers. 9 We sought to identify risk of recurrent infection and hospital readmission based on commonly used discharge ANC thresholds to better inform the appropriate ANC threshold for safe discontinuation of empiric antibiotics and discharge home.
METHODS

Cohort construction
With Institutional Review Board approval, using an institutional database, an initial cohort was developed of 463 patients who were diagnosed with a childhood malignancy from 2007 to 2010, <23 years of age at the time of diagnosis, and treated at the Monroe Carell Jr. Children's Hospital at Vanderbilt, a comprehensive cancer hospital that treats all types of childhood cancer and performs stem cell transplants.
A review was then conducted using the electronic medical record to identify episodes of fever in those with ANC < 500/ l between 2007 and 2012. Fever was defined as a temperature ≥38.0 • C for >1 hr or ≥38.3 • C for any duration. 10 Severe neutropenia was defined as ANC < 500/ l 10 and 549 episodes were identified in 228 patients. All patients were started on empiric intravenous (IV) antibiotics on the day of admission. Episodes were subsequently excluded if the patient did not have a central venous catheter (CVC) at presentation, if they had a preceding febrile event, or received antibiotics within 7 days of the identified episode, or if the patient had received a stem cell transplant within 30 days prior to the episode. Episodes were also excluded if the patient had an identified bacterial infection (blood stream or site infection) that required treatment with targeted antibiotics during the episode, or if the patient had not been afebrile for at least 24 hr when discharged. The resultant cohort of 350 discrete episodes was divided based on ANC values at discharge with subgroups of ANC < 100/ l (n = 14), ANC = 100-199/ l (n = 51), ANC = 200-499/ l (n = 125), and ANC ≥ 500/ l (n = 160). A consort diagram can be found in Figure 1 . It has previously been shown that monocyte production recovery often precedes neutrophil production recovery and that absolute monocyte count (AMC) or absolute phagocyte count (APC), defined as ANC + AMC, could be used as an early indicator of bone marrow recovery. 4, 11 Thus, a subanalysis was conducted where the cohort was divided into APC categories at discharge APC >500/ l (n = 277) and APC <500/ l (n = 73).
Demographic and exposure data were collected for all F&N episodes in the cohort. This included patient age, gender, oncologic diagnosis, number of days since last IV chemotherapy, type of CVC, number of days that the CVC had been in place, and the clinical 
Outcomes
Primary outcomes assessed at 7 days postdischarge were presentation with new fever, receipt of empiric antibiotics, readmission for fever, identification of new blood stream infection (BSI), and mortality; these were compared between ANC at discharge subgroups. As there were some episodes when empiric antibiotics were stopped prior to discharge, a subanalysis of the same outcomes was assessed within 7 days of empiric antibiotic cessation. Since a discharge ANC of 200/ l and ANC of 100/ l were the two most common thresholds used for discharge at Vanderbilt, a comparison was sought to see if using the lower threshold could prevent unnecessary hospital days. Thus, a subset of episodes was identified in which the patient's ANC dropped below 200/ l, subsequently rose to greater than 100/ l, the patient met other standard discharge criteria, and had no further documented indication for ongoing hospitalization apart from neutropenia. The number of additional hospital days spent while awaiting further ANC increase was then collected for this subset.
Statistical analysis
Episode characteristics were summarized by subgroups defined by ANC at discharge (<100/ l, 100-199/ l, 200-499/ l, and ≥500/ l) and overall. For continuous variables, median with lower and upper quartiles were reported. For categorical variables, frequencies and percentages were shown. For each of the predefined 7-day postdischarge outcomes (new fever, received empiric antibiotics, readmitted for fever, and new BSI), the event frequency and rate were reported and compared using Pearson's 2 test among the ANC subgroups. The same outcomes were also compared between those with an APC <500/ l and APC ≥ 500/ l. All statistical inferences were assessed at a two-sided 5% significant level. All statistical analyses were performed using R version 3.3 statistical software. 12 Table 1 provides characteristics of the entire cohort and each ANC at discharge subgroup. Acute lymphoblastic leukemia was the underlying oncologic diagnosis more common in those with discharge ANC of <100/ l (11/14, 78.6%) and 100-199/ l (36/ 51, 70.6%) compared to those with discharge ANC of 200-499/ l (64/125, 51.2%) and ≥ 500/ l (46/160, 28.8%), P ≤ 0.01. A port-a-cath was the predominant type of CVC in all subgroups but was more common in those discharged with ANC < 500/ l with P < 0.01. The percentage of patients receiving G-CSF since their last cycle of chemotherapy increased by discharge subgroup with ANC of <100/ l (1/14, 7.1%), 100-199/ l (6/51, 11.8%), 200-299/ l (35/125, 28.0%), and ≥500/ l (103/160, 64.4%) and P < 0.01. There also was some variance in age, gender, and median number of days the central line had been in place (all P < 0.01).
RESULTS
Cohort characteristics
A limited number of episodes had patients receiving antiinfection prophylaxis including 307 on Pneumocystis jiroveci prophylaxis, 63 on fluconazole, 16 on acyclovir, seven on voriconazole, four on nitrofurantoin, one on levofloxacin, one on ciprofloxacin, and one on cefixime. Table 2 summarizes all 7-day postdischarge outcomes, all of which did not reach statistical significance; however some numeric differences will be described. Across the entire cohort (n = 350), new fever occurred within 7 days of discharge in 26 (7.4%) episodes. The occurrence of new fever was slightly higher for episodes with discharge ANC ≥ 500/ l (13/160, 8.1%) compared to those with discharge ANC 200-499/ l (8/125, 6.4%) and ANC 100-199/ l (2/51, 3.9%, P = 0.57). Occurrence of new fever was also higher for episodes with discharge ANC < 100/ l (3/14, 21.4%) compared with those who had discharge ANC ≥100/ l (23/336, 6.8%, P = 0.13). Receipt of new empiric antibiotics occurred within 7 days of discharge in 20 (5.7%) episodes ( Table 2 ). The overall rate of restarting empiric antibiotics within each ANC cohort was similar between episodes with discharge ANC 100-199/ l (2/51, 3.9%), ANC 200-499/ l (5/125, 4.0%), and ANC ≥ 500/ l (11/160, 6.9%, P = 0.50). Rate of restarting empiric antibiotics was higher for episodes with discharge ANC < 100/ l (2/14, 14.3%, P = 0.41).
Seven-day outcomes
Readmission for fever occurred within 7 days of discharge in 17 (4.6%) episodes (Table 2 ). Similar readmission rates were seen for episodes with discharge ANC of 100-199/ l (2/51, 3.9%), 200-499/ l (5/125, 4.0%), and ≥500/ l (8/160, 5.0%, P = 0.90) but trended higher for episodes with discharge ANC < 100/ l (2/14, 14.3%, P = 0.30).
New BSI was identified upon readmission in three (0.9%) episodes. One new BSI occurred in episodes with discharge ANC < 100/ l, ANC 200-499/ l, and ANC ≥ 500/ l. Empiric antibiotics were stopped prior to discharge in 41 (11.7%) of the episodes. The main reason documented for early stoppage of antibiotics included need for additional inpatient chemotherapy (9), need for rehabilitation (1), need for IV pain control (4), need for stem cell collection (2), nutritional concerns (11), and no discernable reason from the chart (14) . The ANC was already ≥200/ l at time of antibiotic cessation in 38 (92.7%) of these episodes. None of these episodes resulted in a new fever or need to restart empiric antibiotics while still admitted to the hospital off antibiotics. Within 7 days of discharge, a new fever occurred in five (12.2%) episodes, and readmission occurred in three (7.3%) of these episodes. In no episodes were IV antibiotics stepped down oral antibiotics. Table 3 provides characteristics for all 17 episodes that resulted in hospital readmission within 7 days of discharge. ANC at readmission was <500/ l in 10 (58.8%) of the episodes, though two of these patients had received an additional cycle of chemotherapy prior to discharge from the initial F&N hospitalization. One patient with a discharge ANC < 100/ l was diagnosed with Streptococcus pneumoniae bacteremia upon readmission but stabilized on antibiotic therapy.
Characteristics of readmission episodes
There was one death that occurred within 72 hr of readmission from overwhelming sepsis related to Clostridium tertium bacteremia. This patient on initial F&N admission had empiric antibiotics discontinued 3 days prior to discharge and then received further chemotherapy prior to discharge from the initial F&N hospitalization. There was also one patient with a discharge ANC >500/ l who was diagnosed with Candida albicans fungemia upon readmission but had no adverse outcome. Clostridium difficile colitis was diagnosed in three (17.6%) of the readmitted patients. Two episodes were excluded from this study due to the presence of fever within 24 hr of discharge.
One of these episodes resulted in readmission on day 4 postdischarge and the patient was diagnosed with C. difficile colitis upon readmission.
Additional hospital days
In the subset of 217 episodes where the patient had a post-nadir ANC ≥100/ l and no further indication for ongoing hospitalization apart from neutropenia, 94 (43.3%) patients remained hospitalized awaiting further ANC increase, resulting in 126 additional days of hospitalization (Table 4) . Ten (10.6%) of these patients had an ANC of 100-199/ l at discharge. Four (4.3%) patients were readmitted for fever within 7 days of discharge, with ANCs at discharge of 
APC at discharge
The rate of readmission for fever was higher between those with a discharge APC <500/ l (7/73, 9.6%) versus APC ≥ 500/ l (10/277, 3.6%); however this did not reach statistical significance (Supplementary Table S1 ). Readmission occurred in two (7.1%) episodes where the patient had a discharge APC <500/ l and ANC 100-199/ l (n = 28). A new BSI was not isolated upon readmission in either episode. No readmissions or new BSI occurred in episodes where the patient had a discharge APC ≥ 500/ l and ANC < 200/ l (n = 23).
DISCUSSION
Evidence-based, pediatric-specific guidelines are available for the management of F&N. 3 These guidelines include the standard discharge criteria that the patient must be afebrile for at least 24 hr, blood cultures remain negative for 48 hr, and the patient must have evidence of bone marrow recovery at the time of discharge. ANC is used as a surrogate marker of bone marrow recovery. 4 Prior studies have
shown that patients discharged with an ANC < 500/ l are not at increased risk of adverse infectious outcomes, even in cases of prolonged neutropenia lasting greater than 7 days, if they otherwise met standard discharge criteria and had hematologic evidence of bone marrow recovery. 5, 6, 8, [13] [14] [15] Previously published guidelines suggest a post-nadir ANC > 100/ l as a reasonable threshold value for evidence of bone marrow recovery and safety of discharge, but no studies cited in this recommendation specifically compared patient outcomes for threshold ANC values below 500/ l. 3 A more recent study showed that patients with a discharge ANC of <100/ l had a threefold increase in readmission for fever compared to patients with a discharge ANC ≥ 100/ l. 16 However, this study also did not stratify outcomes for patients with discharge ANC values between 100/ l and 500/ l. The present study is the first to look specifically at outcomes within subgroups based on commonly used discharge ANC thresholds ≤500/ l. Furthermore, this study only included patients with a CVC, as the presence of a CVC is associated with increased risk of severe infection. 17, 18 Seven-day postdischarge readmission rates and recurrence of fever were similar between ANC at discharge subgroups of 100-199/ l, 200-499/ l, and ≥500/ l, and there were few detected readmission bloodstream infections in any of the groups. One patient in the cohort died of overwhelming sepsis from C. tertium bacteremia upon readmission, but this patient had a discharge ANC of 290/ l and had received another cycle of chemotherapy just prior to discharge. The readmission rate and new BSI occurrence in the episodes with discharge ANC < 100/ l were numerically higher; however the sample size of this group was too low to draw conclusions.
Empiric antibiotics were stopped prior to discharge in a small percentage (11.7%) of episodes. A new fever did not occur prior to discharge in any of these episodes. Three of these episodes resulted in readmission, two of which occurred within 7 days of discharge and all of which had an ANC > 200/ l on the day initial empiric antibiotics were stopped. Therefore, timing of antibiotic cessation had little impact on 7-day outcome comparisons between subgroups.
Overall, there is not enough data to make a conclusion regarding the safety of discharge for an ANC < 100/ l. However, these data suggest there are equivalent outcomes for patients discharged at an ANC of 100-199/ul compared to those discharged at a higher threshold to support safe discharge home without continued antibiotic therapy in those with an ANC > 100/ul, supporting published guidelines.
Given that monocyte count recovery may precede neutrophil count recovery, some providers look at a rise in AMC or APC as an early indicator of imminent marrow recovery when considering discharge of patients admitted for F&N. 4, 11 In the present study, all primary outcomes, including readmission rate, were higher for episodes with APC <500/ l compared to those with APC ≥ 500/ l. Of note, no readmission or new BSI occurred for episodes with APC ≥ 500/ l and ANC <200/ l, but only seven of these episodes had an ANC < 100/ l.
These results suggest that an APC >500/ l at discharge, even in the setting of an ANC < 100/ l could be a reasonable strategy. This would need to be evaluated in a larger cohort before any conclusions can be made.
The use of ANC > 100/ l as threshold for discharge home off empiric antibiotics can result in additional benefit with respect to hospital costs and decreased risk for nosocomial infection. In this cohort, a significant percentage (43.3%) of patients who were otherwise ready for discharge were kept an additional 126 hospital days for further count recovery despite a post-nadir ANC > 100/ l. Receipt of G-CSF did not have a substantial impact on accrual of additional hospital days.
Furthermore, four (4.3%) of these patients were readmitted despite being kept additional hospital days, a readmission rate similar to the overall cohort readmission rate (4.6%). Two of three patients in the cohort diagnosed with C. difficile colitis upon readmission were kept additional hospital days with continued antibiotic treatment. Although this was not the focus of this study, it does underscore the risk of nosocomial infection associated with all F&N admissions and prolonged treatment with empiric antibiotics.
There are several limitations to this study. Data were obtained through retrospective chart review and relied on accurate and detailed documentation in the medical record. This was particularly notable when determining indications for on-going hospitalization after standard discharge criteria had been met. The chart was checked for parameters such as poor oral intake status and need for IV medications, but this could have been incompletely documented. Episodes were excluded if a bacterial infection from any source of fever was identified and treated with targeted antimicrobial therapy. The sample size is modest and thus has limited power. Event rate was low for all primary outcomes. Particularly of note, very few patients were discharged with an ANC < 100 l, so there was only 56% power for comparing new fever rate between ANC 100-199/ l and <100/ l group to achieve a statistical significance at 5% type I error rate. This limits the conclusions that can be made about discharging patients with an ANC < 100/ l.
Overall, the equivalent safety outcomes for patients discharged at an ANC of 100-199/ l compared to those discharged at a higher threshold support the previous recommendation of a post-nadir ANC > 100/ l as a safe threshold for discharge home off empiric antibiotics. Furthermore, adherence to this recommendation has the potential to reduce unnecessary health care utilization and nosocomial morbidity. Prospective implementation is needed to assess for changes in outcomes and health care utilization to establish the safety and efficacy of using this threshold and further solidify the recommendation.
